1. Home
  2. ORIC vs OLP Comparison

ORIC vs OLP Comparison

Compare ORIC & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORIC
  • OLP
  • Stock Information
  • Founded
  • ORIC 2014
  • OLP 1982
  • Country
  • ORIC United States
  • OLP United States
  • Employees
  • ORIC N/A
  • OLP N/A
  • Industry
  • ORIC Biotechnology: Pharmaceutical Preparations
  • OLP Real Estate Investment Trusts
  • Sector
  • ORIC Health Care
  • OLP Real Estate
  • Exchange
  • ORIC Nasdaq
  • OLP Nasdaq
  • Market Cap
  • ORIC 633.7M
  • OLP N/A
  • IPO Year
  • ORIC 2020
  • OLP N/A
  • Fundamental
  • Price
  • ORIC $10.33
  • OLP $25.52
  • Analyst Decision
  • ORIC Strong Buy
  • OLP Strong Buy
  • Analyst Count
  • ORIC 9
  • OLP 1
  • Target Price
  • ORIC $18.75
  • OLP $28.00
  • AVG Volume (30 Days)
  • ORIC 601.8K
  • OLP 51.6K
  • Earning Date
  • ORIC 03-10-2025
  • OLP 03-04-2025
  • Dividend Yield
  • ORIC N/A
  • OLP 7.05%
  • EPS Growth
  • ORIC N/A
  • OLP 51.11
  • EPS
  • ORIC N/A
  • OLP 1.63
  • Revenue
  • ORIC N/A
  • OLP $89,142,000.00
  • Revenue This Year
  • ORIC N/A
  • OLP N/A
  • Revenue Next Year
  • ORIC N/A
  • OLP $4.71
  • P/E Ratio
  • ORIC N/A
  • OLP $15.66
  • Revenue Growth
  • ORIC N/A
  • OLP N/A
  • 52 Week Low
  • ORIC $6.33
  • OLP $19.25
  • 52 Week High
  • ORIC $16.65
  • OLP $30.45
  • Technical
  • Relative Strength Index (RSI)
  • ORIC 59.58
  • OLP 37.95
  • Support Level
  • ORIC $9.69
  • OLP $25.08
  • Resistance Level
  • ORIC $11.15
  • OLP $26.25
  • Average True Range (ATR)
  • ORIC 0.82
  • OLP 0.58
  • MACD
  • ORIC 0.18
  • OLP 0.02
  • Stochastic Oscillator
  • ORIC 75.08
  • OLP 27.89

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Share on Social Networks: